926934-01-2

Basic information

• Product Name: 4-[4-[(2-Bromophenyl)methyl]-1-piperazinyl]benzoic Acid Ethyl Ester
• Synonyms: 4-[4-[(2-Bromophenyl)methyl]-1-piperazinyl]benzoic Acid Ethyl Ester;Benzoic acid, 4-[4-[(2-broMophenyl)Methyl]-1-piperazinyl]-, ethyl ester;Ethyl 4-(4-(2-BroMobenzyl)piperazin-1-yl)benzoate;ethyl 4-[4-[(2-bromophenyl)methyl]piperazin-1-yl]benzoate
• CAS NO: 926934-01-2
• Molecular Formula: C₂₀H₂₃BrN₂O₂
• Molecular Weight: 403.31282
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 926934-01-2.mol

Chemical Properties

• Boiling Point: 507.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.337±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform, DMSO, Methanol
• PKA: 6.67±0.10(Predicted)
• CAS DataBase Reference: 4-[4-[(2-Bromophenyl)methyl]-1-piperazinyl]benzoic Acid Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-[(2-Bromophenyl)methyl]-1-piperazinyl]benzoic Acid Ethyl Ester(926934-01-2)
• EPA Substance Registry System: 4-[4-[(2-Bromophenyl)methyl]-1-piperazinyl]benzoic Acid Ethyl Ester(926934-01-2)

Safety Data

• Hazardous Substances Data: 926934-01-2(Hazardous Substances Data)

Usage

Chemical Properties

Light Brown Solid

Upstream product

• 80518-57-6 ethyl 4-(piperazin-1-yl)benzoate 
• 6630-33-7 ortho-bromobenzaldehyde 
• 3433-80-5 1-Bromo-2-bromomethyl-benzene 
• 451-46-7 4-fluorobenzoic acid ethyl ester 

Downstream Products

• 926934-09-0 4-[4-(4'-fluoro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-03-4 4-[4-(3'-methoxy-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-06-7 4-[4-(3'-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-07-8 4-[4-(4'-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-04-5 4-[4-(4'-methoxy-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-08-9 4-(4-[1,1';4',1'']terphenyl-2-ylmethyl-piperazin-1-yl)-benzoic acid ethyl ester 
• 926934-05-6 4-[4-(2'-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-10-3 4-[4-(4'-trifluoromethyl-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-02-3 4-[4-(2-pyridin-3-ylbenzyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-11-4 4-[4-(4'-methanesulfonyl-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoic acid ethyl ester 
• 926934-16-9 4-[4-(2-pyridin-3-yl-benzyl)-piperazin-1-yl]-benzoic acid 
• 916204-05-2 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1-yl)benzoic acid 

Relevant articles and documents

INHIBITING B-CELL LYMPHOMA 2 (BCL-2) AND RELATED PROTEINS

Novel compounds inhibiting anti-apoptosis proteins B-cell lymphoma 2 (Bcl-2) and Bcl-XL include compounds of formula (I) and formula (II) disclosed herein, as well as liposome compositions comprising Bcl-2 inhibitor compounds. These compositions are usefu

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

BCL-2 INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to Bcl-2 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL

Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy. Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy. We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation. Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2. This study culminated in the identification of 2, which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, respectively. Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.